Immunotherapeutic Potential of the Yellow Fever Virus Vaccine Strain 17D for Intratumoral Therapy in a Murine Model of Pancreatic Cancer
<b>Objective</b>: We evaluate the immunotherapeutic potential of the yellow fever virus vaccine strain 17D (YFV 17D) for intratumoral therapy of pancreatic cancer in mice. <b>Methods</b>: The cytopathic effect of YFV 17D on mouse syngeneic pancreatic cancers cells were studie...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/1/40 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587373788004352 |
|---|---|
| author | Alina S. Nazarenko Yulia K. Biryukova Kirill N. Trachuk Ekaterina A. Orlova Mikhail F. Vorovitch Nikolay B. Pestov Nick A. Barlev Anna I. Levaniuk Ilya V. Gordeychuk Alexander S. Lunin Grigory A. Demyashkin Petr V. Shegai Andrei D. Kaprin Aydar A. Ishmukhametov Nadezhda M. Kolyasnikova |
| author_facet | Alina S. Nazarenko Yulia K. Biryukova Kirill N. Trachuk Ekaterina A. Orlova Mikhail F. Vorovitch Nikolay B. Pestov Nick A. Barlev Anna I. Levaniuk Ilya V. Gordeychuk Alexander S. Lunin Grigory A. Demyashkin Petr V. Shegai Andrei D. Kaprin Aydar A. Ishmukhametov Nadezhda M. Kolyasnikova |
| author_sort | Alina S. Nazarenko |
| collection | DOAJ |
| description | <b>Objective</b>: We evaluate the immunotherapeutic potential of the yellow fever virus vaccine strain 17D (YFV 17D) for intratumoral therapy of pancreatic cancer in mice. <b>Methods</b>: The cytopathic effect of YFV 17D on mouse syngeneic pancreatic cancers cells were studied both in vitro and in vivo and on human pancreatic cancers cells in vitro. <b>Results</b>: YFV 17D demonstrated a strong cytopathic effect against human cancer cells in vitro. Although YFV 17D did not exhibit a lytic effect against Pan02 mouse cells in vitro, a single intratumoral administration of 17D caused a delay in tumor growth and an increase in median survival by 30%. Multiple injections of 17D did not further improve the effect on tumor growth; however, it notably extended the median survival. Furthermore, preliminary immunization with 17D enhanced its oncotherapeutic effect. <b>Conclusions</b>: Intratumoral administration of yellow fever virus vaccine strain 17D delayed tumor in a murine model of pancreatic cancer. The fact that YFV 17D in vitro affected human cancer cells much more strongly than mouse cancer cells appears promising. Hence, we anticipate that the in vivo efficacy of YFV-17D-based oncolytic therapy will also be higher against human pancreatic carcinomas compared to its effect on the mouse pancreatic tumor. |
| format | Article |
| id | doaj-art-9c1d235a06a0468bb5578a0f1e754d4b |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-9c1d235a06a0468bb5578a0f1e754d4b2025-01-24T13:51:45ZengMDPI AGVaccines2076-393X2025-01-011314010.3390/vaccines13010040Immunotherapeutic Potential of the Yellow Fever Virus Vaccine Strain 17D for Intratumoral Therapy in a Murine Model of Pancreatic CancerAlina S. Nazarenko0Yulia K. Biryukova1Kirill N. Trachuk2Ekaterina A. Orlova3Mikhail F. Vorovitch4Nikolay B. Pestov5Nick A. Barlev6Anna I. Levaniuk7Ilya V. Gordeychuk8Alexander S. Lunin9Grigory A. Demyashkin10Petr V. Shegai11Andrei D. Kaprin12Aydar A. Ishmukhametov13Nadezhda M. Kolyasnikova14Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, RussiaLaboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, RussiaLaboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, RussiaLaboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, RussiaLaboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, RussiaLaboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, RussiaLaboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, RussiaLaboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, RussiaDepartment of Organization and Technology of Production of Immunobiological Preparations, Institute for Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 117418, RussiaLaboratory for Modelling Immunobiological Processes with Experimental Clinic of Callitrichidae, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, RussiaLaboratory of Histology and Immunohistochemistry, Institute for Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 117418, RussiaDepartment of Digital Oncomorphology, National Medical Research Centre of Radiology, 2nd Botkinsky pass 3, Moscow 125284, RussiaDepartment of Digital Oncomorphology, National Medical Research Centre of Radiology, 2nd Botkinsky pass 3, Moscow 125284, RussiaLaboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, RussiaLaboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS (Institute of Poliomyelitis), Moscow 108819, Russia<b>Objective</b>: We evaluate the immunotherapeutic potential of the yellow fever virus vaccine strain 17D (YFV 17D) for intratumoral therapy of pancreatic cancer in mice. <b>Methods</b>: The cytopathic effect of YFV 17D on mouse syngeneic pancreatic cancers cells were studied both in vitro and in vivo and on human pancreatic cancers cells in vitro. <b>Results</b>: YFV 17D demonstrated a strong cytopathic effect against human cancer cells in vitro. Although YFV 17D did not exhibit a lytic effect against Pan02 mouse cells in vitro, a single intratumoral administration of 17D caused a delay in tumor growth and an increase in median survival by 30%. Multiple injections of 17D did not further improve the effect on tumor growth; however, it notably extended the median survival. Furthermore, preliminary immunization with 17D enhanced its oncotherapeutic effect. <b>Conclusions</b>: Intratumoral administration of yellow fever virus vaccine strain 17D delayed tumor in a murine model of pancreatic cancer. The fact that YFV 17D in vitro affected human cancer cells much more strongly than mouse cancer cells appears promising. Hence, we anticipate that the in vivo efficacy of YFV-17D-based oncolytic therapy will also be higher against human pancreatic carcinomas compared to its effect on the mouse pancreatic tumor.https://www.mdpi.com/2076-393X/13/1/40virotherapycancer immunotherapy17Dyellow fever vaccineintratumoral administrationPDAC |
| spellingShingle | Alina S. Nazarenko Yulia K. Biryukova Kirill N. Trachuk Ekaterina A. Orlova Mikhail F. Vorovitch Nikolay B. Pestov Nick A. Barlev Anna I. Levaniuk Ilya V. Gordeychuk Alexander S. Lunin Grigory A. Demyashkin Petr V. Shegai Andrei D. Kaprin Aydar A. Ishmukhametov Nadezhda M. Kolyasnikova Immunotherapeutic Potential of the Yellow Fever Virus Vaccine Strain 17D for Intratumoral Therapy in a Murine Model of Pancreatic Cancer Vaccines virotherapy cancer immunotherapy 17D yellow fever vaccine intratumoral administration PDAC |
| title | Immunotherapeutic Potential of the Yellow Fever Virus Vaccine Strain 17D for Intratumoral Therapy in a Murine Model of Pancreatic Cancer |
| title_full | Immunotherapeutic Potential of the Yellow Fever Virus Vaccine Strain 17D for Intratumoral Therapy in a Murine Model of Pancreatic Cancer |
| title_fullStr | Immunotherapeutic Potential of the Yellow Fever Virus Vaccine Strain 17D for Intratumoral Therapy in a Murine Model of Pancreatic Cancer |
| title_full_unstemmed | Immunotherapeutic Potential of the Yellow Fever Virus Vaccine Strain 17D for Intratumoral Therapy in a Murine Model of Pancreatic Cancer |
| title_short | Immunotherapeutic Potential of the Yellow Fever Virus Vaccine Strain 17D for Intratumoral Therapy in a Murine Model of Pancreatic Cancer |
| title_sort | immunotherapeutic potential of the yellow fever virus vaccine strain 17d for intratumoral therapy in a murine model of pancreatic cancer |
| topic | virotherapy cancer immunotherapy 17D yellow fever vaccine intratumoral administration PDAC |
| url | https://www.mdpi.com/2076-393X/13/1/40 |
| work_keys_str_mv | AT alinasnazarenko immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT yuliakbiryukova immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT kirillntrachuk immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT ekaterinaaorlova immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT mikhailfvorovitch immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT nikolaybpestov immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT nickabarlev immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT annailevaniuk immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT ilyavgordeychuk immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT alexanderslunin immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT grigoryademyashkin immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT petrvshegai immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT andreidkaprin immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT aydaraishmukhametov immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer AT nadezhdamkolyasnikova immunotherapeuticpotentialoftheyellowfevervirusvaccinestrain17dforintratumoraltherapyinamurinemodelofpancreaticcancer |